Company intelligence / Profile preview
Immunwork
Taipei, Taipei City, Taiwanimmunwork.com ↗
- Ownership
- Private
- Development stage
- Phase 1
01
Overview
Immunwork’s two ultra-long acting drug candidates developed using the Fatty Acid Bundle platform—TE‑8105 and TE‑8214—have entered human clinical trials. Both have demonstrated excellent tolerability and no significant adverse effects so far.
- Therapeutic areas
- OncologyEndocrinologyCardiovascularMetabolic Disorders
- Modalities
- Antibody-drug conjugates (ADC)Antibody-radionuclide conjugates (ARC)Ultra-long acting therapeutic peptides/proteins (Fatty Acid Bundle platform)T-E pharmaceuticals (targeting-effector drugs)
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
Beyond the preview
Go deeper on Immunwork.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunwork.